ADPT - Company ID 0001478320
The table below shows Adaptive Biotechnologies Corp's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $276.98M | $178.96M | $170.28M | $185.31M | $154.34M | $98.38M |
| Cost of revenue | $71.36M | $72.08M | $75.55M | $57.91M | $49.30M | $22.53M |
| Gross profit | - | - | - | - | - | - |
| R&D | $93.77M | $102.95M | $122.12M | $141.76M | $142.34M | $116.07M |
Adaptive Biotechnologies Corp reported annual revenue of $276.98M for fiscal year 2025. That is up 54.8% from $178.96M in fiscal 2024. Over the 9 fiscal years shown, annual revenue grew from $38.45M (FY 2017) to $276.98M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $72.70M |
| $72.81M |
| $83.93M |
| $88.53M |
| $74.50M |
| $49.54M |
| Operating income | -$57.12M | -$162.55M | -$227.03M | -$200.19M | -$208.97M | -$152.82M |
| Income tax | $0.00 | $0.00 | $0.00 | - | - | - |
| Net income | -$59.50M | -$159.49M | -$225.25M | -$200.19M | -$207.28M | -$146.23M |
| EPS (diluted) | -$0.39 | -$1.08 | -$1.56 | -$1.40 | -$1.48 | -$1.11 |